{
  "source": "PA-Notification-Revuforj.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1465-1\nProgram Prior Authorization/Notification\nMedication Revuforj® (revumenib)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nRevuforj (revumenib) is a menin inhibitor indicated for the treatment of relapsed or refractory\nacute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and\npediatric patients 1 year and older.\n2. Coverage Criteria a:\nA. Patients less than 19 years of age\n1. Revuforj will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Acute Leukemia\n1. Initial Authorization\na. Revuforj will be approved based on all of the following criteria:\n(1) Diagnosis of acute leukemia\n-AND-\n(2) Disease is relapsed or refractory\n-AND-\n(3) Positive for lysine methyltransferase 2A gene (KMT2A) translocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Revuforj will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Revuforj therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\nC. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram an",
    " initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Revuforj [package insert]. Syndax Pharmaceuticals, Inc; Waltham, MA; November 2024.\nProgram Prior Authorization/Notification - Revuforj® (revumenib)\nChange Control\n1/2025 New program\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}